In:
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), Vol. 71, No. 9 ( 2016-09-01), p. 2654-2662
Abstract:
We sought to evaluate associations between CD4 at ART initiation (AI), achieving CD4 〉 750 cells/mm3 (CD4 〉 750), long-term immunological recovery and survival. Methods This was a prospective observational cohort study. We analysed data from ART-naive patients seen in 1996–2012 and followed ≥3 years after AI. We used Kaplan–Meier (KM) methods and log-rank tests to compare time to achieving CD4 〉 750 by CD4 at AI (CD4-AI); and Cox regression models and generalized estimating equations to identify factors associated with achieving CD4 〉 750 and mortality risk. Results Of 1327 patients, followed for a median of 7.9 years, 〉 85% received ART for ≥75% of follow-up time; 64 died. KM estimates evaluating likelihood of CD4 〉 750 during 5 years of follow-up, stratified by CD4-AI 〈 50, 50–199, 200–349, 350–499 and 500–750, were 20%, 25%, 56%, 80% and 87%, respectively (log-rank P 〈 0.001). In adjusted models, CD4-AI ≥200 (versus CD4-AI 〈 200) was associated with achievement of CD4 〉 750 [adjusted HR (aHR) = 4.77]. Blacks were less likely than whites to achieve CD4 〉 750 (33% versus 49%, aHR = 0.77). Mortality rates decreased with increasing CD4-AI (P = 0.004 across CD4 strata for AIDS causes and P = 0.009 for non-AIDS death causes). Among decedents with CD4-AI ≥50, 56% of deaths were due to non-AIDS causes. Conclusions Higher CD4-AI resulted in greater long-term CD4 gains, likelihood of achieving CD4 〉 750, longer survival and decreased mortality regardless of cause. Over 80% of persons with CD4-AI ≥350 achieved CD4 〉 750 by 4 years while 75% of persons with CD4-AI 〈 200 did not. These data confirm the hazards of delayed AI and support early AI.
Type of Medium:
Online Resource
ISSN:
1460-2091
,
0305-7453
Language:
English
Publisher:
Oxford University Press (OUP)
Publication Date:
2016
detail.hit.zdb_id:
1467478-6
SSG:
15,3
Permalink